NCT06006819 Prognostic Markers of Acute Heart Failure With Chronic Kidney Disease
| NCT ID | NCT06006819 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cheng-Hsin General Hospital |
| Condition | Chronic Kidney Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 155 participants |
| Start Date | 2023-01-01 |
| Primary Completion | 2025-12-23 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 155 participants in total. It began in 2023-01-01 with a primary completion date of 2025-12-23.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Acute heart failure (AHF) is defined as new or worsening of symptoms and signs of heart failure and is the most frequent cause of unplanned hospital admission in elderly patients. N-terminal pro-brain natriuretic peptide (NT-pro-BNP) is one of the most developed prognostic markers for AHR patients and. NT-pro-BNP has limitations in terms of diagnostic or predictive accuracy in patients with chronic kidney disease (CKD). Plasma proteomics have the potential to examine underlying pathophysiological and prognostic roles, so we compared the plasma proteomic signature to predict outcomes of patients with or without CKD hospitalized for AHF.
Eligibility Criteria
Inclusion Criteria: * hospitalized for acute heart failure Exclusion Criteria: * initial serum NT-proBNP level \<300ng/ml, pregnancy, amputated, and end-stage renal disease under regular dialysis
Contact & Investigator
Shang Feng Yang, MD
PRINCIPAL INVESTIGATOR
Cheng-Hsin General Hospital
Frequently Asked Questions
Who can join the NCT06006819 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 90 Years, studying Chronic Kidney Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06006819 currently recruiting?
Yes, NCT06006819 is actively recruiting participants. Contact the research team at samyang1223@gmail.com for enrollment information.
Where is the NCT06006819 trial being conducted?
This trial is being conducted at Taipei, Taiwan.
Who is sponsoring the NCT06006819 clinical trial?
NCT06006819 is sponsored by Cheng-Hsin General Hospital. The principal investigator is Shang Feng Yang, MD at Cheng-Hsin General Hospital. The trial plans to enroll 155 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.